EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma

Brian D Tran, Irene Peris, Ethan Wurman, Averie Huang, Gabrielle Hodges Onishi, Jiang Hu, Rita A Avelar, Erika A Newman, Analisa DiFeo, Caitlin M O'Connor, Goutham Narla

Journal of Biological Chemistry · 2026

DOI: 10.1016/j.jbc.2026.111298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Brian D Tran und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Protein Phosphatase 2, N-Myc Proto-Oncogene Protein, Proto-Oncogene Proteins c-myc. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Michigan Medical Center Rogel Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk neuroblastoma is one of the most common and deadliest pediatric solid tumors. Proliferation, differentiation, and treatment resistance have been linked to the amplification of MYCN. Although N-Myc has proven to be a difficult therapeutic target, our group and others have previously demonstrated that a small-molecule targeting PP2A, DT-061, drives c-Myc degradation in MYC-driven cancers. This results from its ability to bias PP2A toward heterotrimers that contain the B56α regulatory subunit, which dephosphorylates the S62 c-Myc residue, affecting protein stability and driving its proteasomal degradation. Interestingly, despite a high degree of sequence homology in the phosphodegron of c-Myc and N-Myc, the role of PP2A-B56α in regulating the analogous S62 residue on N-Myc is unknown. Here, we show how N-Myc protein expression is significantly reduced after PP2A reactivation in neuroblastoma cell lines. Treatment with DT-061 combined with its inactive competitive antagonist, DT-766, and the proteasome inhibitor, MG-132, reversed this effect on the loss of N-Myc protein expression, suggesting that PP2A-B56α modulation affects N-Myc stability via the proteasomal degradation pathway. A loss in cell viability and inhibition of the colony formation potential of neuroblastoma cells accompanied this loss in N-Myc expression. Conversely, these effects were abrogated when the N-Myc S62 phosphosite was mutated. In a xenograft model, we observed tumor growth inhibition upon DT-061 treatment, along with a reduction in N-Myc protein expression in vivo. Combined, these results highlight the importance of the PP2A tumor suppressor in regulating MYCN oncogenic signaling and open new potential treatment regimens for high-risk neuroblastoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaProtein Phosphatase 2N-Myc Proto-Oncogene ProteinProto-Oncogene Proteins c-mycHumansProteolysisAnimalsCell Line, TumorCell ProliferationMiceThiazoles

Stichwörter der Autor:innen

N-myccancercancer therapymolecular glueneuroblastomaprotein phosphatase 2 (PP2A)protein serine/threonine phosphatase (PSP)protein stability

Substanzen

Protein Phosphatase 2N-Myc Proto-Oncogene ProteinProto-Oncogene Proteins c-myc5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-oneThiazoles

Autor:innen und Institutionen

  • Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA; Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA; Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA; Section of Pediatric Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA; Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: gnarla@umich.ed…

Förderung

  • University of Michigan Medical Center Rogel Cancer Center

Zitieren

APA

Tran, B. D., Peris, I., Wurman, E., Huang, A., Hodges Onishi, G., Hu, J., Avelar, R. A., Newman, E. A., DiFeo, A., O'Connor, C. M., & Narla, G. (2026). The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.111298

Vancouver

Tran BD, Peris I, Wurman E, Huang A, Hodges Onishi G, Hu J, et al. The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.111298

BibTeX
@article{Tran2026,
  author = {Tran, Brian D and Peris, Irene and Wurman, Ethan and Huang, Averie and Hodges Onishi, Gabrielle and Hu, Jiang and Avelar, Rita A and Newman, Erika A and DiFeo, Analisa and O'Connor, Caitlin M and Narla, Goutham},
  title = {The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma},
  journal = {Journal of Biological Chemistry},
  year = {2026},
  doi = {10.1016/j.jbc.2026.111298}
}
Kostenlos starten →